Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 2c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
EPS Growth %: -60.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -60.5%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $37.4 million versus the consensus estimate of $38.28 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- Toro Company (TTC) Tops Q3 EPS by 3c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
